Champions Oncology (CSBR)
(Delayed Data from NSDQ)
$5.02 USD
-0.04 (-0.79%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $5.10 +0.08 (1.59%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
CSBR 5.02 -0.04(-0.79%)
Will CSBR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CSBR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CSBR
Champions Oncology, Inc. (CSBR) Reports Q3 Loss, Tops Revenue Estimates
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings and Revenue Estimates
CSBR: What are Zacks experts saying now?
Zacks Private Portfolio Services
ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates
Implied Volatility Surging for Champions Oncology (CSBR) Stock Options
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Lags Revenue Estimates
Other News for CSBR
Craig-Hallum downgrades Champions Oncology to Hold amid challenging environment
Craig-Hallum gets more bearish on Champions Oncology, downgrades shares
Champions Oncology, Inc. (CSBR) Q3 2024 Earnings Call Transcript
Earnings Scheduled For March 12, 2024
Champions Oncology Non-GAAP EPS of -$0.16, revenue of $12M